Results 351 to 360 of about 125,713 (396)

Chronic Myelomonocytic Leukaemia and Atypical Chronic Myeloid Leukaemia

1992
Chronic myelomonocytic leukaemia (CMML) has attracted interest in two contexts in recent years. First, the FAB Cooperative Group [3] has classified it as a myelodysplastic syndrome (MDS) characterised by the presence in the peripheral blood of more than 1.0 × 109/1 monocytes but otherwise identical with one of the named variants of MDS, except in those
I. Krsnik, P. C. Srivastava, D. A. G. Galton   +2 more
openaire   +2 more sources

Epidemiology of chronic myeloid leukaemia (CML)

Best Practice & Research Clinical Haematology, 2009
Reliable epidemiological information on chronic myeloproliferative disorders (CMPDs), notably Philadelphia (Ph)/BCR-ABL-positive chronic myeloid leukaemia (CML), is rare. Incidence rates vary from 0.6 to 2.0 cases per 100 000 inhabitants, increase with age and are higher in men than in women.
Maren Rohrbacher, Joerg Hasford
openaire   +3 more sources

Treatment-free remission in patients with chronic myeloid leukaemia

Nature Reviews Clinical Oncology, 2020
D. Ross, T. Hughes
semanticscholar   +1 more source

The blast phase of chronic myeloid leukaemia

Best Practice & Research Clinical Haematology, 2009
The blast phase of chronic myelogeneous leukaemia (BP-CML) still remains a difficult entity to understand pathogenetically and to treat. In recent years, advances have been made in our understanding of the molecular biology and the pathogenesis of this disorder. Although three new agents have been introduced with some success for treating this disease,
openaire   +3 more sources

Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.

The Lancet Oncology, 2018
S. Saussele, J. Richter, J. Guilhot, F. Gruber, H. Hjorth-Hansen, A. Almeida, J. Janssen, J. Mayer, Perttu Koskenvesa, P. Panayiotidis, U. Olsson‐Strömberg, J. Martínez-López, P. Rousselot, H. Vestergaard, H. Ehrencrona, V. Kairisto, Katerina Machova Polakova, Martin C. Müller, S. Mustjoki, M. Berger, A. Fabarius, W. Hofmann, A. Hochhaus, M. Pfirrmann, F. Mahon   +24 more
semanticscholar   +1 more source

Restoring metabolism of myeloid cells reverses cognitive decline in ageing

Nature, 2021
Congcong Wang, Miles H Linde, Amit U Joshi   +2 more
exaly  

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.

The Lancet Oncology, 2010
F. Mahon, D. Réa, J. Guilhot, F. Guilhot, F. Huguet, F. Nicolini, L. Legros, A. Charbonnier, A. Guerci, B. Varet, G. Étienne, J. Reiffers, P. Rousselot   +12 more
semanticscholar   +1 more source

Treatment of chronic myeloid leukaemia

Baillière's Clinical Haematology, 1987
N. C. Allan, Patricia Shepherd
openaire   +2 more sources

Transplantation in chronic myeloid leukaemia

The Lancet, 2002
Alvaro Urbano-Ispizua, Alois Gratwohl, Helen Baldomero   +2 more
openaire   +3 more sources

Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?

Nature Reviews Clinical Oncology, 2017
G. Rosti, F. Castagnetti, G. Gugliotta, M. Baccarani   +3 more
semanticscholar   +1 more source